Publications by authors named "Kamrul-Hasan A"
Background: Endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) regulate islet cell function. GLP-1 receptor agonists (GLP-1RAs) have been associated with an elevated risk of acute pancreatitis. Data on the pancreatic safety of tirzepatide (a dual GLP-1 and GIP agonist) and its effects on islet cell function in randomized controlled trials (RCTs) are scarce.
View Article and Find Full Text PDFObjective: No meta-analysis has holistically analyzed and summarized the efficacy and safety of the novel once-weekly basal insulin efsitora alfa in managing type 1 diabetes (T1D) and type 2 diabetes (T2D).
Methods: Clinical trials involving subjects with T1D and T2D receiving once-weekly efsitora alfa in the intervention arm and once-daily basal insulins in the control arm were searched throughout the electronic databases. The primary outcome assessed was the change from baseline in HbA1c.
Purpose: Early gestational diabetes mellitus (eGDM) refers to elevated blood glucose levels not meeting the criteria for overt diabetes before 20 weeks gestation. Observational studies link eGDM to adverse outcomes, but randomized controlled trial (RCT) evidence on early intervention benefits remains inconclusive. To address this, we performed a systematic review and meta-analysis (SRM) of RCTs on this subject.
View Article and Find Full Text PDFNo meta-analysis has analysed role of cagrilintide as weight-loss medication in obese individuals. Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.
View Article and Find Full Text PDFBackground: Empagliflozin is a relatively newer glucose-lowering drug (GLD) with many extra-glycemic benefits. To date, no study has evaluated the efficacy and safety of empagliflozin in Bangladeshi patients with type 2 diabetes mellitus (T2DM).
Objectives: To assess the efficacy and safety of empagliflozin as an add-on to ongoing GLDs in Bangladeshi adults with uncontrolled T2DM.
Objective: No meta-analysis has been published comparing the efficacy and safety of tirzepatide versus once-daily basal insulins in subjects with type 2 diabetes (T2D) inadequately controlled with oral anti-hyperglycemic drugs (OADs). This meta-analysis was conducted to address this knowledge gap.
Methods: Randomized controlled trials (RCTs) involving subjects with T2D inadequately controlled with OADs and receiving tirzepatide in intervention arm and basal insulins in control arm as add-on therapy were searched throughout the electronic databases.
Article Synopsis
- The glucagon receptor antagonist volagidemab is a novel monoclonal antibody that helps manage type-1 diabetes (T1D) by lowering insulin needs and reducing risks like diabetic ketoacidosis.
- A systematic review of three randomized controlled trials (98 patients) found that volagidemab significantly decreased the total daily dose of insulin and average blood glucose levels compared to a placebo.
- Additionally, while it increased the time patients spent within the target blood glucose range, there was no significant change in the occurrence of adverse events or hypoglycemia when compared to the placebo group.
To date, no meta-analysis has analyzed the efficacy and safety of tirzepatide as an anti-obesity medication in individuals without diabetes. This meta-analysis was undertaken to address this knowledge gap. Electronic databases were searched for randomized controlled trials (RCTs) involving individuals with obesity without diabetes receiving tirzepatide in the intervention arm and placebo in the control arm.
View Article and Find Full Text PDFObeticholic acid (OCA) has emerged as a promising drug in the management of nonalcoholic fatty liver disease (NAFLD). This meta-analysis aimed to analyse the therapeutic effect of OCA on NAFLD. Randomized controlled trials (RCTs) involving patients with NAFLD receiving OCA in the intervention arm and placebo in the control arm were searched throughout the electronic databases.
View Article and Find Full Text PDFMarked alterations in the normal female hormonal milieu in the perimenopausal period significantly affect women's health, leading to decreased well-being, psychological distress, and impaired quality of life. Common menopausal symptoms include hot flashes, sleep and mood changes, fatigue, weight gain, and urogenital disturbances. Clinicians often neglect mood swings and disrupted sleep, although those can significantly limit the productivity of women and impair their cognitive function and mental health.
View Article and Find Full Text PDFMultiple observation studies and meta-analysis have linked growth hormone (GH) deficiency with metabolic-dysfunction-associated steatotic liver disease (MASLD). No meta-analysis has analysed the efficacy and safety of GH therapy on different aspects of MASLD. We undertook this meta-analysis to address this gap in knowledge.
View Article and Find Full Text PDFArticle Synopsis
- A meta-analysis was conducted to assess the efficacy and safety of ertugliflozin compared to a placebo in patients with Type 2 diabetes (T2D), filling a gap in existing research.
- The analysis included seven randomized controlled trials with a total of 7283 subjects, showing that ertugliflozin significantly reduced HbA1c levels and fasting plasma glucose compared to placebo, with a higher percentage of patients achieving HbA1c targets.
- While ertugliflozin's safety profile was generally comparable to placebo, it was associated with a higher risk of genital mycotic infections, though both doses (5 mg and 15 mg) showed similar efficacy and safety overall.
Helicobacter pylori (H. pylori) is a major cause of peptic ulcer disease (PUD), which needs effective eradication of the organism to heal ulcers and prevent a recurrence. In recent years, increasing resistance of H.
View Article and Find Full Text PDFCongenital Adrenal Hyperplasia: Experience from Dhaka Shishu (Children) Hospital, Bangladesh.
Mymensingh Med J
October 2024
Article Synopsis
- There is limited data on congenital adrenal hyperplasia (CAH) in Bangladesh, prompting a study to gather information and identify key issues related to the condition.
- The analysis focused on 60 pediatric patients from Dhaka Shishu Hospital, revealing that 66.7% had salt-wasting form, with significant misassignments in gender at initial presentation.
- The study highlights the need for earlier CAH diagnosis to prevent severe health crises and emphasizes raising awareness for effective case identification and referral in resource-limited settings.
Aims: While randomized controlled trials data on the long-term effect of glucose-lowering drugs (GLDs) on liver-related outcomes are lacking, population-based studies have evaluated the associations of GLDs with liver-related outcomes in individuals with type 2 diabetes (T2D). we aimed to conduct a systematic review of population-based studies evaluating the effects of GLDs on liver-related outcomes in people with T2D.
Methods: PubMed, Web of Science, and Embase databases were systematically searched for population-based studies testing the associations of GLDs with liver-related outcomes in individuals with T2D and no liver disease other than non-alcoholic fatty liver disease (NAFLD) from inception to 23 February 2024.
Background: No meta-analysis has holistically analyzed and summarized the safety and therapeutic efficacy of the newer RNA interference (RNAi) therapies, olezarsen, plozasiran, and zodasiran, in managing conditions associated with hypertriglyceridemia (HTG).
Methods: Randomized controlled trials (RCTs) involving patients with HTG or mixed hyperlipidemia (MHL) receiving either olezarsen, plozasiran, or zodasiran in the intervention arm and a placebo in the control arm were searched through electronic databases. The primary outcome was the safety profile of the drugs studied; secondary outcomes included the percent change from baseline (CFB) in the lipid levels, including triglyceride (TG).
Background: No comprehensive meta-analysis has examined and consolidated the effectiveness and safety of anagliptin in treating type 2 diabetes mellitus (T2D). To bridge this knowledge gap, we undertook this meta-analysis.
Methods: Randomized controlled trials involving patients with T2D receiving anagliptin were sought after through electronic databases.
Article Synopsis
- MRKH syndrome is a rare condition that leads to the absence or underdevelopment of the uterus and vagina in females, affecting their reproductive health.
- A 17-year-old girl with MRKH was admitted for primary amenorrhea and poorly controlled diabetes, despite having normal growth and no significant medical or family history.
- Clinical evaluations revealed normal external genitalia, a blind vaginal pouch, absence of the uterus and cervix, and an ectopic left kidney, while her blood glucose levels remained poorly managed.
Obesity and hypothyroidism are interlinked. In this prospective study, 142 children and adolescents (mean age 140±34 months, girls 54.2%) either with obesity or overweight were included from the patients attending at the Endocrine out-patient clinic of Dhaka Shishu (Children) Hospital during a period from March, 2017 to February, 2020 and were assessed for thyroid function.
View Article and Find Full Text PDFGlobal warming and endocrine disorders are intertwined issues posing significant challenges. Greenhouse gases emanating from human activities drive global warming, leading to temperature rise and altered weather patterns. South Asia has experienced a noticeable temperature surge over the past century.
View Article and Find Full Text PDFBackground: No meta-analysis has holistically analyzed and summarized the therapeutic efficacy and safety of albiglutide in type 2 diabetes (T2D). This meta-analysis addresses this knowledge gap.
Methods: Randomized controlled trials involving patients with T2D receiving albiglutide in the intervention arm and either a placebo or an active comparator in the control arm were searched through electronic databases.
Background: Flibanserin, approved for the treatment of hypoactive sexual desire disorder (HSDD) in females, has demonstrated diverse therapeutic and adverse effect (AE) prospects in the extant randomized controlled trials (RCTs). This meta-analysis aimed to characterize the outcomes of flibanserin use in these patients comprehensively.
Methods: RCTs involving women with HSDD receiving flibanserin in the intervention arm and placebo in the control arm were sought after throughout the electronic databases.